| Literature DB >> 27423900 |
Justice Nonvignon1, Genevieve Cecilia Aryeetey1, Shamwill Issah2, Patrick Ansah3, Keziah L Malm4, Winfred Ofosu5, Titus Tagoe5, Samuel Agyei Agyemang1, Moses Aikins6.
Abstract
BACKGROUND: In Ghana, malaria is endemic and perennial (with significant seasonal variations in the three Northern Regions), accounting for 33 % of all deaths among children under 5 years old, with prevalence rates in children under-five ranging from 11 % in Greater Accra to 40 % in Northern Region. Ghana adopted the WHO-recommended Seasonal Malaria Chemoprevention (SMC) strategy with a trial in the Upper West Region in 2015. The objective of this study was to estimate the cost-effectiveness of seasonal malaria chemoprevention.Entities:
Keywords: Ghana; Incremental cost-effectiveness ratios; Seasonal malaria chemoprevention; Under-five
Mesh:
Substances:
Year: 2016 PMID: 27423900 PMCID: PMC4947302 DOI: 10.1186/s12936-016-1418-z
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Fig. 1Algorithm for seasonal malaria chemoprevention (SMC)
Cost-effectiveness of smc programme in the upper west region
| Item | Region |
|---|---|
| Target population (children under 5 years) | 148,104.00 |
| Number of fully dosed children | 118,208.00 |
| Cost of SMC programme (US$, 2015 prices) | |
| Total financial cost | 1142,040.80 |
| Financial cost per fully dosed child | 9.66 (95 % CI 7.46–14.21) |
| Economic cost (provider perspective) | 2663,697.18 |
| Economic cost (societal perspective) | 7961,153.27 |
| Effect of SMC programme | |
| Additional number of cases averted | 24,881 |
| Additional number of child deaths averted | 808 |
| Cost-effectiveness ratios (ICERs) (US$, 2015 prices) | |
| Provider perspectivea | |
| Economic cost per fully dosed child | 22.53 (95 % CI 21.08–28.06) |
| Economic cost per additional case averted | 107.06 (95 % CI 99.75–121.48) |
| Economic cost per additional child death averted | 3298.36 (95 % CI 3073.26–3742.64) |
| Societal perspectiveb | |
| Economic cost per fully dosed child | 67.35 (95 % CI 63.56–77.86) |
| Economic cost per additional case averted | 319.96 (95 % CI 284.23–366.38) |
| Economic cost per additional child death averted | 9858.02 (95 % CI 8757.11–11,288.08) |
aIncludes only provider-related costs incurred on delivery of the intervention
bIncludes cost incurred on delivery of the intervention, donations and the valued time and other expenses of caregivers and volunteers
Fig. 2Financial cost profile by activity (%)
Fig. 3Financial cost per fully dosed child per district
Fig. 4Percentage of fully dosed child vs. financial cost per district
Fig. 5Economic cost profile by activity (%)
Sensitivity analysis results
| Parameter | Change | ICERs (provider perspective) | ICERs (societal perspective) | ||
|---|---|---|---|---|---|
| Cost per additional case averted | Cost per additional death averted | Cost per additional case averted | Cost per additional death averted | ||
| Base estimates | Base case scenario | 107.06 | 3298.38 | 319.96 | 9858.02 |
| Medicine cost | Application of 16.1 % inflation rate | 112.55 | 3467.77 | 325.46 | 10,027.43 |
| Discount rate | Increasing the discount rate from 3 to 5 % | 107.24 | 3304.16 | 320.15 | 9863.81 |
| National min. wage rate | Use of national daily minimum wage rate of GHS7 rather than agric wage of GHS 11.36 | 97.33 | 2328.26 | 228.48 | 6958.60 |
| Mortality rate | 10 deaths per 1000 population | 107.60 | 2998.65 | 319.96 | 7039.40 |
| Mortality rate | 4.5 deaths per 1000 population | 107.60 | 6853.74 | 319.96 | 20,484.19 |
| SMC coverage | Increase in SMC administrative coverage from 60 to 80 % | 107.60 | 10,654.79 | 319.96 | 31,996.31 |
| SMC protective efficacy | Decrease in protective efficacy from 80 to 38.5 % | 222.45 | 23,997.27 | 664.86 | 71,102.91 |
Fig. 6Financial cost per child by other preventive interventions
Fig. 7Economic cost per additional death averted